Summary:
- The U.S. FDA has approved Pfizer's RSV (respiratory syncytial virus) vaccine, ABRYSVO, for adults aged 18-59 who are at increased risk of severe disease.
- ABRYSVO is the first RSV vaccine approved for this age group, providing protection against a common respiratory virus that can cause severe illness, particularly in older adults and those with underlying medical conditions.
- The approval is based on clinical trials showing ABRYSVO to be safe and effective in reducing the risk of RSV-associated lower respiratory tract illness in the target population.